We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

143 hedge funds and large institutions have $915M invested in Avidity Biosciences in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 32

25% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 20

9.2% more ownership

Funds ownership: 107.21% → 116.41% (+9.2%)

3% more funds holding

Funds holding: 139 → 143 (+4)

22% less capital invested

Capital invested by funds: $1.17B → $915M (-$251M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

64% less call options, than puts

Call options by funds: $244K | Put options by funds: $674K

Holders
143
Holders Change
+4
Holders Change %
+2.88%
% of All Funds
2.25%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
25
Increased
64
Reduced
32
Closed
20
Calls
$244K
Puts
$674K
Net Calls
-$430K
Net Calls Change
-$3.1M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$65.3M
2
State Street
State Street
Massachusetts
+$22.7M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$17.2M
4
CAC
Cowen and Company
New York
+$13M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.41M

Top Sellers

1
Federated Hermes
Federated Hermes
Pennsylvania
-$36.3M
2
APM
Avidity Partners Management
Texas
-$19.4M
3
CC
Commodore Capital
New York
-$9.07M
4
FLSM
Frazier Life Sciences Management
California
-$7.67M
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$6.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$118M +$65.3M +5,203,807 +96%
RI
2
RTW Investments
New York
$74.2M +$3.8M +302,611 +5%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$74.1M -$2.26M -180,144 -3%
RCM
4
RA Capital Management
Massachusetts
$71.2M – – –
State Street
5
State Street
Massachusetts
$68.6M +$22.7M +1,812,533 +41%
BlackRock
6
BlackRock
New York
$63.9M +$1.57M +125,321 +2%
CAC
7
Cowen and Company
New York
$62.4M +$13M +1,036,137 +23%
Vanguard Group
8
Vanguard Group
Pennsylvania
$44M +$6.09M +485,468 +14%
CAM
9
Cormorant Asset Management
Massachusetts
$29M – – –
ACA
10
Avoro Capital Advisors
New York
$27.8M – – –
Artisan Partners
11
Artisan Partners
Wisconsin
$23.9M +$3.12M +248,577 +13%
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$22.1M +$17.2M +1,370,920 +220%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$21.1M +$7.98M +636,583 +50%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$16M +$1.71M +136,517 +10%
BC
15
Boxer Capital
California
$12.4M – – –
Morgan Stanley
16
Morgan Stanley
New York
$12.2M -$1.93M -153,867 -12%
CC
17
Casdin Capital
New York
$9.43M – – –
ACM
18
Alethea Capital Management
Washington
$9.42M – – –
BBA
19
Baker Bros. Advisors
New York
$8.87M -$2.57M -204,600 -20%
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$8.32M +$9.41M +750,000 New
Bank of America
21
Bank of America
North Carolina
$7.61M +$3.51M +280,031 +69%
5VM
22
5AM Venture Management
California
$7.38M – – –
Northern Trust
23
Northern Trust
Illinois
$7.23M +$628K +50,093 +8%
Rafferty Asset Management
24
Rafferty Asset Management
New York
$6.74M +$2.84M +226,589 +59%
Goldman Sachs
25
Goldman Sachs
New York
$6.16M -$5.74M -457,640 -45%
1
2 3 4 5

RNAM Hedge Fund Activity: Q2 2023 in Review

143 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2023, worth a combined $915M — down 22% from $1.17B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RNAM positions and 20 closed out — a net gain of 5 holders — while 64 added to existing stakes and 32 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $65.3M. The largest seller was Federated Hermes, exiting entirely with an estimated $36.3M sold.

  • 143 institutional investors held Avidity Biosciences (RNAM) as of Q2 2023, up from 139 in Q1 2023.
  • Funds reported $915M of Avidity Biosciences stock for Q2 2023, down 22% quarter-over-quarter.
  • 25 funds opened new Avidity Biosciences positions in Q2 2023 and 20 closed out, a net change of +5 holders.
  • The largest Avidity Biosciences buyer in Q2 2023 was Fidelity Investments, an estimated $65.3M added.
  • The largest Avidity Biosciences seller in Q2 2023 was Federated Hermes, an estimated $36.3M sold.

Based on aggregated 13F filings for Q2 2023.